All News

Post-cure care for hepatitis C can reduce the risk of liver disease progression in those with advanced fibrosis and ongoing risk factors for liver injury.

Conducted by the FDA, an analysis follows a series of recalls for some generic versions of the angiotensin II receptor blocker (ARB) medicines containing nitrosamine impurities that do not meet the agency’s safety standards.

Selecting an accreditation agency should be determined by the local business environment and needs.

Top news of the week from Specialty Pharmacy Times.

Top news of the day across the health care landscape.

Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

I firmly believe that overall pharmacy knowledge should increase over time.

Younger cancer survivors and those with high deductible private insurance plans experienced the greatest financial burden.

Top news of the day across the health care landscape.

Because high triglycerides have been associated with an increased risk for CVD, lowering this lab value should also reduce circulatory system risks.

A novel inhaled product was approved in late 2018 for Parkinson Disease.

Nonmyeloablative hematopoietic stem cell transplant found to prolong time to multiple sclerosis disease progression compared with disease-modifying therapies.

Torrent Pharmaceuticals Limited has expanded its voluntary recall of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP.

An inhaled medication for a disease that does not affect the lungs may prove to be a promising concept in the treatment of chronic diseases.

The new indication would allow treatment-experienced patients with HIV to switch to Pifeltro in combination with other HIV medications or Delstrigo.

Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.

This is the first time an anti-PD-1 therapy has demonstrated a survival benefit in this patient population.

Top news of the day across the health care landscape

Top news of the day across the health care landscape

Two lawsuits filed against Walgreens have been settled with the national drug store chain agreeing to pay a total of more than $260 million.

The report authors noted that people with type 1 diabetes spent $5,705 on insulin in 2016, up from $2,864 in 2012.